GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (OTCPK:VBIZF) » Definitions » EPS without NRI

VBIZF (Viva Biotech Holdings) EPS without NRI : $-0.00 (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings EPS without NRI?

Viva Biotech Holdings's earnings per share without non-recurring items for the six months ended in Dec. 2023 was $-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Viva Biotech Holdings's EPS without NRI or its related term are showing as below:

VBIZF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.8   Med: 46.3   Max: 135.1
Current: -19.8

During the past 8 years, Viva Biotech Holdings's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 135.10% per year. The lowest was -19.80% per year. And the median was 46.30% per year.

VBIZF's 3-Year EPS without NRI Growth Rate is ranked worse than
76.75% of 1213 companies
in the Biotechnology industry
Industry Median: 4.8 vs VBIZF: -19.80

Viva Biotech Holdings's EPS (Diluted) for the six months ended in Dec. 2023 was $-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01.

Viva Biotech Holdings's EPS (Basic) for the six months ended in Dec. 2023 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.00.


Viva Biotech Holdings EPS without NRI Historical Data

The historical data trend for Viva Biotech Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings EPS without NRI Chart

Viva Biotech Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial 0.03 0.02 0.03 -0.01 0.01

Viva Biotech Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 - -0.01 -

Competitive Comparison of Viva Biotech Holdings's EPS without NRI

For the Biotechnology subindustry, Viva Biotech Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viva Biotech Holdings's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's PE Ratio without NRI falls into.



Viva Biotech Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viva Biotech Holdings  (OTCPK:VBIZF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Viva Biotech Holdings EPS without NRI Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Viva Biotech Holdings Business Description

Traded in Other Exchanges
Address
735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.

Viva Biotech Holdings Headlines